< back to all PPMI Presentations

The Parkinson Progression Marker Initiative (PPMI) ? Baseline PD, healthy, and SWEDD data

Parkinsons Progression Marker Initiative
 
2013-06-18
MDS: Sydney, Australia
Download Presentation: MDS-2013 PPMI V1-0km.pdf
 
Abstract:
Objective: The goal of the Parkinson Progression Marker Initiative (PPMI) is to identify clinical, imaging and biospecimen biomarkers of PD progression, establish standardized methods of acquisition and analysis of biomarker data that could be utilized in multi-center clinical trials and provide rapid ongoing public access to PPMI data and biospecimen.
Background: Lack of progression biomarkers has been a major roadblock to studies investigating potential disease modifying PD drugs.
Methods: Recently diagnosed PD, healthy volunteers (HV) and subjects with scans without dopaminergic de?cit (SWEDD) have been enrolled at 24 clinical sites and will be followed longitudinally for clinical, imaging and biospecimen biomarkers using standardized data acquisition protocols. All study data is integrated into the PPMI study database. Access to data and biospecimens is available at www.ppmi-info.org.
Results: As of 01DEC2012 PPMI has enrolled 329 PD, mean age 61.8, (66% Male:34% Female) 160 HV, mean age 60 (60% Male:40% Female) and 51 SWEDD mean age 60.6, (67% Male:33% Female). Duration of disease for PD was 6.9 mo and 8.5 mo for SWEDD. The total MDS-UPDRS for PD was 33.5 compared to 4.5 for HV and 28.8 for SWEDD. Baseline MoCA, GDS, and SCOPAAUT were 27.1, 2.3, 9.7 for PD subjects, 28.3, 1.4, 5.9 for HV and 27.2, 3.2, 13.5 for SWEDD. CSF was acquired from more than 95% of all subjects. Dopamine transporter (DAT) imaging, used as an inclusion criteria, excluded 12?15% from the PD cohort due to SWEDD. DAT striatal binding ratio (SBR) for PD is 3.97 vs. 6.65 for HV. Over 37,500 downloads and 19 biospecimen requests from the PPMI website have already occurred.
Conclusions: Recruitment and comprehensive assessment of PD and HV subjects in PPMI is feasible. Acquisition of CSF from study subjects has been successful. Public access of PPMI data and biospecimen has resulted in wide use of PPMI data and application for distribution of biospecimen for investigator research. Longitudinal follow-up is underway. A prodromal-PPMI cohort de?ned by hyposmia, REM behavior disorder and/or LRRK2 mutation, plus DAT de?cit has been added.